This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Unity Biotechnology raises $116mm through Series B round; $35mm extension added
18 Aug 2017
Unity Biotechnology Inc. raised $116mm through its Series B round from new investors Arch Venture Partners, Baillie Gifford, Fidelity Management & Research Co., Partner Fund Management, and Venrock, along with Bezos Expeditions and returning backers Wuxi PharmaTech and Mayo Clinic Ventures. Unity is developing therapies to selectively eliminate senescent cells from the body to treat diseases of aging. Series B proceeds will help expand R&D activities and advance the first preclinical candidates (for inflammatory joint diseases and ophthalmic conditions) into clinical trials.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?